{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T05:10:09Z","timestamp":1745039409091,"version":"3.37.3"},"reference-count":34,"publisher":"Wiley","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Respiratory Journal"],"published-print":{"date-parts":[[2021,5,25]]},"abstract":"<jats:p>Real-world evidence regarding the effectiveness of prulifloxacin in the treatment of acute exacerbations of chronic bronchitis (AECB) is limited. Therefore, this study aimed to assess the rates and time to symptom improvement and resolution in patients with moderate-to-severe AECB who were given prulifloxacin in the routine care in Greece. This observational, prospective study, conducted in 15 hospital-based clinics across Greece, enrolled outpatients &gt;40 years old, with moderate-to-severe AECB, for whom the physician had decided to initiate treatment with prulifloxacin. Data were collected at prulifloxacin onset (baseline), 7\u201310 days after baseline, and at least 28 days after therapy completion. Between 23 November 2015 and 27 January 2018, 305 patients (males: 76.4%; mean (standard deviation) (SD) age: 69.7 (9.8) years; Anthonisen type I\/II: 94.8%; chronic bronchitis duration &gt;10 years: 24.9%) were consecutively enrolled. At baseline, &gt;80% had increased sputum volume, cough, dyspnoea, and sputum purulence. Prulifloxacin improved symptoms in 99.7% of the patients after a mean (SD) of 5.47 (3.57) days, while symptoms fully recovered after a mean (SD) of 10.22 (5.00) days in 95.4%. The rate of adverse events related to prulifloxacin was 1.3% (serious: 0.7%). In the routine care in Greece, prulifloxacin was highly effective in moderate-to-severe AECB, while displaying a predictable safety profile.<\/jats:p>","DOI":"10.1155\/2021\/6620585","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T20:06:29Z","timestamp":1622059589000},"page":"1-11","source":"Crossref","is-referenced-by-count":1,"title":["Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: \u0391 Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice\u2014The \u201cAIOLOS\u201d Study"],"prefix":"10.1155","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9541-1010","authenticated-orcid":true,"given":"Konstantinos","family":"Gourgoulianis","sequence":"first","affiliation":[{"name":"University Respiratory Clinic, University General Hospital of Larissa, Larissa 41110, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Ruggieri","sequence":"additional","affiliation":[{"name":"\u0391ngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra del","family":"Vecchio","sequence":"additional","affiliation":[{"name":"\u0391ngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Calisti","sequence":"additional","affiliation":[{"name":"\u0391ngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Comandini","sequence":"additional","affiliation":[{"name":"\u0391ngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Esposito","sequence":"additional","affiliation":[{"name":"\u0391ngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Di Loreto","sequence":"additional","affiliation":[{"name":"\u0391ngelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Tzanakis","sequence":"additional","affiliation":[{"name":"University Respiratory Clinic, University General Hospital of Heraklion (PE.PA.GNI), Heraklion 71110, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2010.02741.x"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2005.09.004"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2001.1208"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-0625-1"},{"key":"5","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2147\/COPD.S106160","article-title":"Acute exacerbation of COPD: is it the \u201cstroke of the lungs\u201d?","volume":"11","author":"G. Hillas","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S27411"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-106-2-196"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm228"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00147806"},{"article-title":"Quinolone- and fluoroquinolone-containing medicinal products","year":"2019","author":"European Medicines Agency","key":"10"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf024"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2005.09.007"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1159\/000063623"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2013.03.014"},{"volume-title":"Prixina Summary of Product Characteristics","year":"2006","author":"National Organization for Medicines","key":"15"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1177\/1753465809352791"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2016.1152236"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.06.002"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.045930"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.2147\/copd.2007.2.1.27"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S91392"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200323010-00001"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-13-5"},{"key":"24","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-Reported Population Health: An International Perspective Based on EQ-5D","author":"A. Szende","year":"2014"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.2147\/copd.s51245"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(00)80053-3"},{"article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease","year":"2021","author":"Global Initiative for Chronic Obstructive Lung Disease","key":"27"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00009604"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.628"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1c167"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1161-x"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.05943"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp020"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-10-119"}],"container-title":["Canadian Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/crj\/2021\/6620585.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crj\/2021\/6620585.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crj\/2021\/6620585.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T20:06:35Z","timestamp":1622059595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/crj\/2021\/6620585\/"}},"subtitle":[],"editor":[{"given":"Theodoros I.","family":"Vassilakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":34,"alternative-id":["6620585","6620585"],"URL":"https:\/\/doi.org\/10.1155\/2021\/6620585","relation":{},"ISSN":["1916-7245","1198-2241"],"issn-type":[{"type":"electronic","value":"1916-7245"},{"type":"print","value":"1198-2241"}],"subject":[],"published":{"date-parts":[[2021,5,25]]}}}